Windlas Biotech Reports Record Sales and Profit Amid Liquidity Concerns in August 2025

Windlas Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 12, 2025, indicate a notable shift in the company's evaluation, with its score rising to 6 from 4 over the past three months.
The financial data reveals several positive trends for Windlas Biotech. Net sales reached a record high of Rs 210.09 crore, marking consistent growth over the last five quarters. Similarly, the operating profit (PBDIT) also peaked at Rs 26.53 crore, reflecting a strong upward trajectory. Profit before tax (PBT) and profit after tax (PAT) both reached their highest levels in the last five quarters, at Rs 18.02 crore and Rs 17.66 crore, respectively. Additionally, earnings per share (EPS) improved to Rs 8.43, indicating enhanced profitability for shareholders.

However, not all aspects are favorable. The company's cash and cash equivalents have dropped to Rs 15.93 crore, the lowest in the last six half-yearly periods, suggesting challenges in short-term liquidity. Furthermore, while non-operating income has increased to Rs 5.24 crore, its sustainability remains uncertain.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.